Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × durvalumab × NET × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 116 Gastrointestinal 100 Genitourinary 33 Breast 24 Head & Neck 21 Gynecologic 16 Sarcoma 8 Other solid neoplasm 7 Dermatologic 7 Tumor-Agnostic 6 Lymphoid 3 Endocrine 3 CNS 3 Other hematologic neoplasm 2 Plasma cell 1 NET 1 Myeloid 1

Conditions

Neuroendocrine Tumors 1

Interventions

lutetium Lu 177 dotatate 18 Everolimus 12 Temozolomide 11 Nivolumab 8 Capecitabine 7 pembrolizumab 6 Sunitinib 6 cabozantinib 5 Magnetic Resonance Spectroscopy 5 lanreotide 4 gallium Ga 68 dotatate 4 Specimen Handling 4 Etoposide 4 177Lu-octreotide, DOTA(0)-Tyr(3)- 4 pazopanib 3 avelumab 3 Octreotide 3 Ipilimumab 3 Injections 3 Fluorodeoxyglucose F18 3 Cyclophosphamide 3 Cisplatin 3 Carboplatin 3 telotristat ethyl 2 surufatinib 2 sintilimab 2 lenvatinib 2 fosbretabulin 2 fludarabine 2 copper dotatate CU-64 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03095274 2025-01-09

DUNE

Grupo Espanol de Tumores Neuroendocrinos

Phase 2 Completed

126 enrolled 18 charts

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡